Comprehensive Stock Comparison
Compare Chemed Corporation (CHE) vs Enhabit, Inc. (EHAB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | CHE | 4.1% revenue growth vs EHAB's -1.1% |
| Value | CHE | Lower P/E (16.8x vs 22.5x) |
| Quality / Margins | CHE | 10.5% net margin vs EHAB's -1.1% |
| Stability / Safety | CHE | Beta 0.27 vs EHAB's 0.56, lower leverage |
| Dividends | CHE | 0.5% yield; 18-year raise streak; EHAB pays no meaningful dividend |
| Momentum (1Y) | EHAB | +62.6% vs CHE's -31.4% |
| Efficiency (ROA) | CHE | 17.2% ROA vs EHAB's -1.0%, ROIC 23.8% vs -7.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Chemed Corporation operates two distinct healthcare and home services businesses. It generates revenue primarily from hospice care services through its VITAS segment (~70% of revenue) and plumbing/drain cleaning services through its Roto-Rooter segment (~30%). The company benefits from strong brand recognition in both sectors—VITAS as a leading hospice provider and Roto-Rooter as a trusted plumbing service name—creating dual moats in specialized healthcare and essential home services.
Enhabit operates a network of home health and hospice care agencies across the United States, providing skilled nursing, therapy services, and end-of-life care to patients in their homes. The company generates revenue primarily from Medicare reimbursements — which account for the vast majority of its income — along with payments from Medicaid, private insurers, and patients. Its competitive advantage lies in its extensive geographic footprint across 34 states, which creates referral network effects and operational scale in a fragmented industry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
EHAB leads in 2 of 6 categories (Valuation Metrics, Total Returns). CHE leads in 2 (Profitability & Efficiency, Analyst Outlook). 2 tied.
Financial Metrics (TTM)
CHE is the larger business by revenue, generating $2.5B annually — 2.4x EHAB's $1.0B. CHE is the more profitable business, keeping 10.5% of every revenue dollar as net income compared to EHAB's -1.1%. On growth, EHAB holds the edge at +3.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CHEChemed Corporation | EHABEnhabit, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $2.5B | $1.0B |
| EBITDAEarnings before interest/tax | $387M | $34M |
| Net IncomeAfter-tax profit | $265M | -$12M |
| Free Cash FlowCash after capex | $325M | $58M |
| Gross MarginGross profit ÷ Revenue | +23.0% | +48.4% |
| Operating MarginEBIT ÷ Revenue | +13.4% | +0.8% |
| Net MarginNet income ÷ Revenue | +10.5% | -1.1% |
| FCF MarginFCF ÷ Revenue | +12.9% | +5.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.1% | +3.9% |
| EPS Growth (YoY)Latest quarter vs prior year | -9.0% | +110.0% |
Valuation Metrics
| Metric | CHEChemed Corporation | EHABEnhabit, Inc. |
|---|---|---|
| Market CapShares × price | $5.8B | $686M |
| Enterprise ValueMkt cap + debt − cash | $5.9B | $1.2B |
| Trailing P/EPrice ÷ TTM EPS | 22.26x | -4.38x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.75x | 22.50x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 17.31x | — |
| Price / SalesMarket cap ÷ Revenue | 2.29x | 0.66x |
| Price / BookPrice ÷ Book value/share | 6.03x | 1.23x |
| Price / FCFMarket cap ÷ FCF | 17.77x | 14.47x |
Profitability & Efficiency
CHE delivers a 27.1% return on equity — every $100 of shareholder capital generates $27 in annual profit, vs $-2 for EHAB. CHE carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to EHAB's 1.03x. On the Piotroski fundamental quality scale (0–9), CHE scores 5/9 vs EHAB's 4/9, reflecting solid financial health.
| Metric | CHEChemed Corporation | EHABEnhabit, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +27.1% | -2.0% |
| ROA (TTM)Return on assets | +17.2% | -1.0% |
| ROICReturn on invested capital | +23.8% | -7.3% |
| ROCEReturn on capital employed | +25.7% | -9.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.15x | 1.03x |
| Net DebtTotal debt minus cash | $69M | $541M |
| Cash & Equiv.Liquid assets | $75M | $28M |
| Total DebtShort + long-term debt | $144M | $570M |
| Interest CoverageEBIT ÷ Interest expense | 112.39x | 0.93x |
Total Returns (with DRIP)
A $10,000 investment in CHE five years ago would be worth $9,392 today (with dividends reinvested), compared to $5,444 for EHAB. Over the past 12 months, EHAB leads with a +62.6% total return vs CHE's -31.4%. The 3-year compound annual growth rate (CAGR) favors EHAB at -3.9% vs CHE's -7.3% — a key indicator of consistent wealth creation.
| Metric | CHEChemed Corporation | EHABEnhabit, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -3.1% | +49.7% |
| 1-Year ReturnPast 12 months | -31.4% | +62.6% |
| 3-Year ReturnCumulative with dividends | -20.3% | -11.3% |
| 5-Year ReturnCumulative with dividends | -6.1% | -45.6% |
| 10-Year ReturnCumulative with dividends | +230.4% | -45.6% |
| CAGR (3Y)Annualised 3-year return | -7.3% | -3.9% |
Risk & Volatility
CHE is the less volatile stock with a 0.27 beta — it tends to amplify market swings less than EHAB's 0.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EHAB currently trades 99.8% from its 52-week high vs CHE's 65.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CHEChemed Corporation | EHABEnhabit, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.27x | 0.56x |
| 52-Week HighHighest price in past year | $623.61 | $13.64 |
| 52-Week LowLowest price in past year | $385.10 | $6.47 |
| % of 52W HighCurrent price vs 52-week peak | +65.7% | +99.8% |
| RSI (14)Momentum oscillator 0–100 | 28.2 | 84.1 |
| Avg Volume (50D)Average daily shares traded | 128K | 419K |
Analyst Outlook
Wall Street rates CHE as "Hold" and EHAB as "Hold". Consensus price targets imply 15.9% upside for CHE (target: $475) vs -0.6% for EHAB (target: $14). CHE is the only dividend payer here at 0.54% yield — a key consideration for income-focused portfolios.
| Metric | CHEChemed Corporation | EHABEnhabit, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold |
| Price TargetConsensus 12-month target | $475.00 | $13.53 |
| # AnalystsCovering analysts | 9 | 11 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | — |
| Dividend StreakConsecutive years of raises | 18 | 0 |
| Dividend / ShareAnnual DPS | $2.20 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +7.5% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 22 | Feb 26 | Change |
|---|---|---|---|
| Chemed Corporation (CHE) | 100 | 90.51 | -9.5% |
| Enhabit, Inc. (EHAB) | 90.96 | 43.08 | -52.6% |
Chemed Corporation (CHE) returned -6% over 5 years vs Enhabit, Inc. (EHAB)'s -46%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Chemed Corporation (CHE) | $1.6B | $2.5B | +60.4% |
| Enhabit, Inc. (EHAB) | $1.1B | $1.0B | -4.0% |
Chemed Corporation's revenue grew from $1.6B (2016) to $2.5B (2025) — a 5.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Chemed Corporation (CHE) | 6.9% | 10.5% | +52.0% |
| Enhabit, Inc. (EHAB) | 7.0% | -15.1% | -317.0% |
Chemed Corporation's net margin went from 7% (2016) to 10% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Chemed Corporation (CHE) | 41.5 | 23.2 | -44.1% |
Chemed Corporation has traded in a 23x–42x P/E range over 9 years; current trailing P/E is ~22x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Chemed Corporation (CHE) | 6.48 | 18.42 | +184.3% |
| Enhabit, Inc. (EHAB) | 19.23 | -3.11 | -116.2% |
Chemed Corporation's EPS grew from $6.48 (2016) to $18.42 (2025) — a 12% CAGR.
Chart 6Free Cash Flow — 5 Years
Chemed Corporation generated $325M FCF in 2025 (+30% vs 2021). Enhabit, Inc. generated $47M FCF in 2024 (-60% vs 2021).
CHE vs EHAB: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CHE or EHAB a better buy right now?
Chemed Corporation (CHE) offers the better valuation at 22.3x trailing P/E (16.8x forward), making it the more compelling value choice. Analysts rate Chemed Corporation (CHE) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CHE or EHAB?
On forward P/E, Chemed Corporation is actually cheaper at 16.8x.
03Which is the better long-term investment — CHE or EHAB?
Over the past 5 years, Chemed Corporation (CHE) delivered a total return of -6.1%, compared to -45.6% for Enhabit, Inc. (EHAB). A $10,000 investment in CHE five years ago would be worth approximately $9K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CHE returned +230.4% versus EHAB's -45.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CHE or EHAB?
By beta (market sensitivity over 5 years), Chemed Corporation (CHE) is the lower-risk stock at 0.27β versus Enhabit, Inc.'s 0.56β — meaning EHAB is approximately 108% more volatile than CHE relative to the S&P 500. On balance sheet safety, Chemed Corporation (CHE) carries a lower debt/equity ratio of 15% versus 103% for Enhabit, Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — CHE or EHAB?
Chemed Corporation (CHE) is the more profitable company, earning 10.5% net margin versus -15.1% for Enhabit, Inc. — meaning it keeps 10.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHE leads at 13.4% versus -11.1% for EHAB. At the gross margin level — before operating expenses — EHAB leads at 48.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CHE or EHAB more undervalued right now?
On forward earnings alone, Chemed Corporation (CHE) trades at 16.8x forward P/E versus 22.5x for Enhabit, Inc. — 5.7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CHE: 15.9% to $475.00.
07Which pays a better dividend — CHE or EHAB?
In this comparison, CHE (0.5% yield) pays a dividend. EHAB does not pay a meaningful dividend and should not be held primarily for income.
08Is CHE or EHAB better for a retirement portfolio?
For long-horizon retirement investors, Chemed Corporation (CHE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.27), 0.5% yield, +230.4% 10Y return). Both have compounded well over 10 years (CHE: +230.4%, EHAB: -45.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CHE and EHAB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. CHE pays a dividend while EHAB does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.